Search by Drug Name or NDC
NDC 00169-4060-90 Victoza 6 mg/mL Details
Victoza 6 mg/mL
Victoza is a SUBCUTANEOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novo Nordisk. The primary component is LIRAGLUTIDE.
MedlinePlus Drug Summary
Liraglutide injection (Victoza) is used with a diet and exercise program to control blood sugar levels in adults and children 10 years of age and older with type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) when other medications did not control levels well enough. Liraglutide injection (Victoza) is also used to reduce the risk of a heart attack, stroke, or death in adults with type 2 diabetes mellitus and heart and blood vessel disease. Liraglutide injection (Victoza) is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated) in adults. Liraglutide injection (Saxenda) is used along with a reduced calorie diet and exercise plan to help certain adults and children 12 years of age and older who weigh 132 pounds (60 kg) or more and who are obese or who are overweight and have weight-related medical problems to lose weight and to keep from gaining back that weight. Liraglutide injection (Saxenda) is not used to treat type 2 diabetes. Liraglutide injection is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Liraglutide injection also slows the emptying of the stomach and may decrease appetite and cause weight loss. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Using medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 00169-4060-90Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Liraglutide Injection
Product Information
NDC | 00169-4060 |
---|---|
Product ID | 0169-4060_fbacd7b4-2565-4292-b1f6-2aff4e467d47 |
Associated GPIs | 2717005000D220 |
GCN Sequence Number | 065344 |
GCN Sequence Number Description | liraglutide PEN INJCTR 0.6 MG/0.1 SUBCUT |
HIC3 | C4I |
HIC3 Description | ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEP.AGONIST) |
GCN | 26189 |
HICL Sequence Number | 036436 |
HICL Sequence Number Description | LIRAGLUTIDE |
Brand/Generic | Brand |
Proprietary Name | Victoza |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | liraglutide |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION |
Route | SUBCUTANEOUS |
Active Ingredient Strength | 6 |
Active Ingredient Units | mg/mL |
Substance Name | LIRAGLUTIDE |
Labeler Name | Novo Nordisk |
Pharmaceutical Class | GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA022341 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00169-4060-90 (00169406090)
NDC Package Code | 0169-4060-90 |
---|---|
Billing NDC | 00169406090 |
Package | 1 SYRINGE, PLASTIC in 1 CARTON (0169-4060-90) / 3 mL in 1 SYRINGE, PLASTIC |
Marketing Start Date | 2010-01-25 |
NDC Exclude Flag | N |
Pricing Information | N/A |